In a more recent extensive biomarker analysis for the IMbrave150 trial, high expression of CD274 and intra-tumor CD8(+) cells density was associated with prolonged patient survival, while high Treg:Teff ratio and expression of HCC tumor markers, such as GPC3 and AFP, were associated with poor outcome[7]. The gene discussed is CD274; the disease is hepatocellular carcinoma.